Product Details
| Clone: | 15G7 |
| |
| Host: | Rat |
| |
| Isotype: | IgG2a |
| |
| Immunogen: | Synthetic peptide corresponding to aa 116-131 of human α-synuclein. |
| |
| UniProt ID: | P37840 |
| |
| Species reactivity: | Human
|
| |
| Crossreactivity: | Does not cross-react with mouse α-synuclein or recombinant β- or γ-synuclein. |
| |
| Applications: | IHC (FS), IHC (PS), IP, WB
|
| |
| Recommended Dilutions/Conditions: | Immunohistochemistry (paraffin sections, 1:5-1:10)
Western Blot (1:5)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Formulation: | Liquid. Hybridoma supernatant containing 0.05% sodium azide. |
| |
| Handling: | Aliquot diluted antibody into smaller volumes prior to freezing. Avoid freeze/thaw cycles. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Synuclein was originally identified in Torpedo californica as a small neuroprotein that localized to the nuclear envelope of neurons and to presynaptic nerve termini. The human homolog was initially termed NACP, a precursor protein to NAC (Non-Ab Component), because of its prevalence in amyloid plaques in Alzheimer’s patients. Later, NACP was recognized as being α-synuclein (α-SYN), a 14kDa protein, belonging to the synuclein family of phosphoproteins that also includes: β-synuclein, γ-synuclein, and synoretin.
α-SYN is recognized as a key component in the development and diagnosis of neurodegenerative synucleinopathic diseases (NSDs), such as Alzheimer’s and Parkinson’s disease. In the past five years, several genetic and post-translational modifications to α-SYN have been elucidated that have been linked to its collaboration in the formation of the classical Lewy bodies (LBs) or Lewy neurites that are associated with neurodegeneration. A study that shed more light on the neurogenesis of autorecessive synucleinopathies (ARSs) was the finding that α-SYN accumulation can occur due to mutations in the E3 ubiquitin ligase.
ARSs only account for a small percentage of NSD. Thus the illustration that α-SYN has a high susceptibility to tyrosine nitration may be the key component in understanding the formation of LBs. Due to the chemical structure of α-SYN, tyrosine nitration readily leads to the formation of oligomers via covalent O,O’-dityrosine bonds (cross-linking). Nitrosylated, wild-type, α-SYN products thus form SDS-insoluble, heat-stable aggregates in vitro that may account for α-SYN inclusions in all forms of NSDs. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Alpha synuclein processing by MMP-3 - implications for synucleinopathies: A. Bluhm, et al.; Behav. Brain Res.
434, 114020 (2022),
Abstract;
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies: B. Permanne, et al.; ACS Chem. Neurosci.
13, 1296 (2022),
Abstract;
Transplantation of Adipose-Derived Stem Cells Alleviates Striatal Degeneration in a Transgenic Mouse Model for Multiple System Atrophy: C. Chang, et al.; Cell Transplant.
29, 963689720960185 (2020),
Abstract;
Full Text
Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy: A. Heras-Garvin, et al.; Mov. Disord.
34, 255 (2019),
Abstract;
Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice: Y.M. Kuo, et al.; Am. J. Neurodegener. Dis.
8, 1 (2019),
Abstract;
Full Text
Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy: G. Minakaki, et al.; Behav. Brain Res.
363, 199 (2019),
Abstract;
Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease: S. Nuber, et al.; Neuron
100, 75 (2018),
Abstract;
Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis: L. Fellner, et al.; BMC Neurosci.
19, 32 (2018),
Abstract;
Full Text
Refolding of helical soluble α-synuclein through transient interaction with lipid interfaces: M. Rovere, et al.; FEBS Lett.
592, 1464 (2018),
Abstract;
Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging: A. Khairnar, et al.; Brain Behav. Immun.
61, 197 (2017),
Abstract;
Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease: A.L. Orr, et al.; Neurochem. Int.
109, 106 (2017),
Abstract;
Full Text
Subcellular Parkinson’s Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration: R. Abdullah, et al.; Mol. Neurobiol.
54, 7639 (2017),
Abstract;
Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications: S. Schafferer, et al.; PLoS One
11, e0150705 (2016),
Application(s): Immunohistochemistry,
Abstract;
Full Text
High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease: F. Macchi, et al.; J. Neurosci. Methods
261, 117 (2016),
Application(s): Western blot,
Abstract;
α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy: B. Ettle, et al.; Acta Neuropathol.
132, 59 (2016),
Abstract;
Full Text
Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype: D. Kuzdas-Wood, et al.; PLoS One
10, e0136575 (2015),
Application(s): Immunohistochemistry,
Abstract;
Full Text
Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters: S.A. Aelvoet, et al.; J. Neurosci.
34, 16518 (2014),
Application(s): Immunocytochemistry and Western Blot on neuroblastoma cells (SHSY5Y),
Abstract;
Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease: K.L. Paumier, et al.; PLoS One
8, e70274 (2013),
Application(s): IHC using trangenic mouse tissue,
Abstract;
Full Text
Bladder dysfunction in a transgenic mouse model of multiple system atrophy: M. Boudes, et al.; Mov. Disord.
28, 347 (2013),
Abstract;
Intact olfaction in a mouse model of multiple system atrophy: F. Krismer, et al.; PLoS One
8, e64625 (2013),
Application(s): IHC using mouse tissue,
Abstract;
Full Text
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia: L. Fellner, et al.; Glia
61, 349 (2013),
Application(s): ICC using mouse cell,
Abstract;
Full Text
Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway: J. Klucken, et al.; Autophagy
8, 754 (2012),
Application(s): ICC using human cells,
Abstract;
Full Text
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis: V.M. Nemani, et al.; Nat Med.
65, 66 (2010),
Abstract;
Full Text
Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia: T. Obi, et al.; Neurology
70, 238 (2008),
Abstract;
Alpha-synuclein overexpression increases cytosolic catecholamine concentration: E.V. Mosharov, et al.; J. Neurosci.
26, 9304 (2006),
Abstract;
Full Text
Lipid rafts mediate the synaptic localization of alpha-synuclein: D.L. Fortin, et al.; J. Neurosci.
24, 6715 (2004),
Abstract;
Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells: J. Wiltfang, et al.; J. Biol. Chem.
276, 42645 (2001),
Abstract;
Full Text
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain: P.J. Kahle, et al.; J. Neurosci.
20, 6365 (2000),
Abstract;
Full Text
Synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies: M. Neumann, et al.; Acta Neuropathol.
100, 568 (2000),
Abstract;
